weight loss with glp-1 agonists Rx Trends: Real-World Data on GLP-1s for glp 1 used for weight

[DOI] [PMC free article] [PubMed] [Google Scholar] 26.Nauck MA, et al

These side effects can usually be reduced by initiating the medication at a low dose and titrating slowly

Cognitive function following 12-weeks exenatide versus placebo The results from the trial describing the ability of exenatide to significantly lower ICP at 12 weeks have been previously published [19]

Collectively, these intertwined metabolic, inflammatory, and hemodynamic processes underpin the development and progression of DKD (Fig

A synergic GLP-1/Acylethanolamide-based combined therapy for MAFLD: studies in rat models

Utility of glucagon-like peptide 1 receptor agonists as anti-obesity medications in liver transplant recipients